In current weeks, Aurora Cannabis ( NYSE: ACB) stock has actually seen new life. It all began with the business launching its third-quarter 2020 results on May 14, which showed 18%income growth from the prior duration. A dedication to further improving its costs also offered financiers a factor to be enthusiastic that profitability may not be simply a pipe dream.
Then, on May 20, the marijuana manufacturer likewise announced it was obtaining Reliva, a cannabidiol (CBD) brand that would allow it to penetrate the U.S. market. As interesting a chance as that may appear at first glimpse, here’s why investors should not put too much stock in it.
It’s entering a currently crowded hemp market
Lots of headings market Aurora’s recent acquisition as the company getting into the U.S. CBD market. While it’s technically real, it should have an asterisk at the very least. All kinds of CBD aren’t legal in the U.S. (federally), and Aurora can’t provide non-hemp items that contain more than 0.3%of tetrahydrocannabinol (THC). U.S. cannabis business that don’t run nationally and rather run within states that permit medical or recreational pot aren’t limited to those constraints. And till the U.S. federal government legalizes medical or recreational marijuana, it’s a limitation Canadian marijuana companies will face.
Image source: Getty Images.
The bright side is that according to research companies BDS Analytics and Arcview Marketing Research, the total CBD market in the U.S. is still anticipated to reach $20 billion by 2024, up from just $1.9 billion in2018 The projection didn’t break out the split between hemp and non-hemp items. And the bad news is that the rosy outlook for CBD doesn’t mean the chance is going to translate into substantial development for Aurora.
That’s since Aurora will not just be taking on other U.S. business for market share, however with Canadian pot stocks that are also aiming to make the most of the chances in the hemp market. The company’s crucial rival, Canopy Development ( NYSE: CGC) is currently in the CBD hemp market in the U.S., and one of the moves it’s making to cut costs is to actually stop farming for hemp at its Springfield, New York area. The pot giant said it had “an abundance of hemp produced in the 2019 growing season” that it was going to offer initially before making more. It’s not just Canopy Development that has an excess of supply, either; it’s an issue for the entire industry.
Julie Lerner, who is CEO of the PanXchange where hemp is traded, confirmed in January that there was far more supply than need for hemp. She expects list prices to come down as an outcome of all the competition. That’s not going to bode well for a business like Aurora, which is attempting to improve on its margins and get closer to profitability.
Having access to countless places does not ensure growth
In the news release revealing the acquisition of Reliva, there wasn’t a great deal of information on how huge of a player the business remains in the hemp market. Aurora referred to Reliva as “a leader in the sale of hemp-derived CBD products in the United States,” there wasn’t anything to measure or validate that other than to say that its products were sold in more than 20,000 U.S. places. According to experts, Reliva’s sales over a 12- month period ending in February totaled $14 million in revenue.
Hemp-derived CBD company Charlotte’s Web ( OTC: CWBHF), offers its items in less locations, and it has far more powerful sales. In the business’s first-quarter outcomes, launched on May 14, Charlotte’s Web announced that its reach went beyond 11,000 locations which its sales for the three-month period totaled $215 million. And although it’s seen a boost in the variety of shops bring its items, that hasn’t translated into substantial growth.
A year earlier, the company recorded sales of $217 million when its products remained in more than 6,000 places. The boost in areas over the previous year hasn’t led to a surge in sales for Charlotte’s Web, and Aurora financiers shouldn’t make the mistake of assuming more places indicate higher income. If there are just limited products offered, or the inventory isn’t moving, the variety of retailers carrying the items may not imply much for the company’s top line.
The move doesn’t make Aurora a much better buy
Aurora expects Reliva to help the Alberta-based pot manufacturer inch better to attaining a positive adjusted revenues prior to income, taxes, devaluation, and amortization (EBITDA) figure. The acquisition may help play a small part in enhancing Aurora’s bottom line, but the business still has a lot of work to do in improving its financials.
The only certainty, it appears, is that the offer will cause more dilution for shareholders. The business expect the offer will close in June, and it will cost Aurora as much as $45 million in shares.
The acquisition is a modest one for Aurora that will assist add to its leading line, but that’s about it; Aurora remains a risky buy, and one quarter and one acquisition isn’t going to change that. The pot stock is still down more than 80%over the past 12 months, especially even worse than the Horizons Cannabis Life Sciences ETF ( OTC: HMLSF), which has fallen by 60%.
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Charlottes Web Holdings. The Motley Fool recommends Charlotte’s Web. The Motley Fool has a disclosure policy.”>